MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
34.17
-0.68
-1.95%
Closed 19:57 05/09 EDT
OPEN
35.43
PREV CLOSE
34.85
HIGH
35.60
LOW
34.15
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
39.54
52 WEEK LOW
21.62
MARKET CAP
6.49B
P/E (TTM)
-9.6780
1D
5D
1M
3M
1Y
5Y
1D
J.P. Morgan Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
TipRanks · 4d ago
Rare Stock Picks In April 2025 - From 16 Discerning Analysts
Seeking Alpha · 4d ago
Major Insider Sales Shake Up BridgeBio Pharma Stock!
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and BridgeBio Pharma (BBIO)
TipRanks · 6d ago
BRIDGEBIO PHARMA INC <BBIO.O>: MIZUHO RAISES TARGET PRICE TO $60 FROM $53
Reuters · 6d ago
Weekly Report: what happened at BBIO last week (0428-0502)?
Weekly Report · 6d ago
U.S. RESEARCH ROUNDUP-Block, Cigna, Wesco International
Reuters · 6d ago
Chord, InMode, Upstart, BridgeBio, Astria: Trending by Analysts
TipRanks · 05/03 09:01
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.